—
C+
C+ The full Closelook — membership. Open the C+ overview

TELIX Pharmaceuticals Ltd (TLX.AU) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — TELIX Pharmaceuticals Ltd

TLX.AU in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Telix Pharmaceuticals develops radiopharmaceuticals, medicines that pair radioactive isotopes with molecules aimed at cancer cells, used for both imaging and treatment. It runs three business lines, precision medicine, therapeutics and manufacturing solutions, and already sells two prostate-cancer imaging agents, Illuccix and Gozellix. Its most advanced treatment candidate is a lutetium-labelled antibody conjugate for advanced prostate cancer, in a late-stage trial, alongside earlier programmes for kidney cancer, brain tumours and bone-marrow conditioning. It is headquartered in Melbourne and operates across several countries including the United States and the United Kingdom.
Where it sits in the stack
Telix carries no seat in Rubin or Halo, our AI-related indices; it sits within the diary's wider healthcare and biotechnology coverage, outside the AI build-out stack the diary otherwise tracks.
Who it is priced against
Closelook has no peer group defined for Telix; the market's natural comparison is Novartis, whose radioligand therapy business competes directly in prostate-cancer treatment.
Why Closelook tracks it
Telix holds no seat in Rubin or Halo, carries no Closelook score, and is not quoted in the diary's editions; it appears only in our routine price readings, without established index coverage.
What the diary watches
The diary watches whether the current pull-back extends below its 50-day average or holds above it, after the stock's recent slide off its high.

TELIX Pharmaceuticals Ltd (TLX.AU) trades on the AU exchange in Australia, classified under Healthcare.

The Closelook company score reads 39/100 composite (momentum 89, quality 27, valuation 17) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for TLX.AU, from the same nightly bakes the boards use. Research diary readings, not advice.

Who it is priced against Biotechnology · 8 names with week and year-to-date

Peer group

Biotechnology

Names in the same industry from the Closelook universe; scored names rank on their Closelook score, the rest on trend state.

Compared against TLX.AU on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Dividends and capital return no distribution in twelve months · buybacks 2 m AUD in FY2025

Dividends and capital return

What TLX.AU pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Buybacks, FY2025 2 m AUD 0.0% of today's market value
  • Share count −2.1% in FY2025
  • Capital returned 2 m AUD in a year of negative free cash flow dividends and buybacks together

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 50/100 · S&P 500 fund at 49, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-18
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 97th percentile of the window, +4.9% over 20 sessions. Factor regime → 2026-09-18
  • Sector × region Health care in Asia-Pacific developed: +4.6% week · −1.9% month · +8.1% quarter · −3.5% yearThe Sector Engine cell this name lives in, from 1621.TSE; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-09-20
  • Sovereign pressure Index 0.07 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-18

FAQ · from the current data · as of 2026-09-19

Quick answers

What is TELIX Pharmaceuticals Ltd (TLX.AU)?

TELIX Pharmaceuticals Ltd trades as TLX.AU on the AU exchange (Australia) and is classified under Healthcare in the Closelook research universe, as of the registry build of 2026-09-19.

Is TLX.AU in a Closelook index?

Not currently — TELIX Pharmaceuticals Ltd is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-19.

What is TELIX Pharmaceuticals Ltd's Closelook composite score?

39 out of 100, with momentum 89, quality 27 and valuation 17 sub-scores, as of 2026-09-19. Scores are Closelook's own research readings, not ratings or investment advice.

Where does TLX.AU trade against its moving averages?

Uptrend stack intact: Trades +12.5% vs the 50-day and +31.3% vs the 200-day average, 2.6% below the 52-week high and +116.1% off the 52-week low. Computed from daily closes. As of 2026-09-18 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does TELIX Pharmaceuticals Ltd do?

Telix Pharmaceuticals develops radiopharmaceuticals, medicines that pair radioactive isotopes with molecules aimed at cancer cells, used for both imaging and treatment. It runs three business lines, precision medicine, therapeutics and manufacturing solutions, and already sells two prostate-cancer imaging agents, Illuccix and Gozellix. Its most advanced treatment candidate is a lutetium-labelled antibody conjugate for advanced prostate cancer, in a late-stage trial, alongside earlier programmes for kidney cancer, brain tumours and bone-marrow conditioning. Closelook has no peer group defined for Telix; the market's natural comparison is Novartis, whose radioligand therapy business competes directly in prostate-cancer treatment.

Where does TELIX Pharmaceuticals Ltd sit in the AI build-out?

Telix carries no seat in Rubin or Halo, our AI-related indices; it sits within the diary's wider healthcare and biotechnology coverage, outside the AI build-out stack the diary otherwise tracks. Telix holds no seat in Rubin or Halo, carries no Closelook score, and is not quoted in the diary's editions; it appears only in our routine price readings, without established index coverage.

Does TELIX Pharmaceuticals Ltd pay a dividend?

No cash distribution shows in TELIX Pharmaceuticals Ltd’s price series over the last three years. In fiscal 2025 the company bought back 2 m AUD of its own shares. The share count fell 2.1% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What does this page show?

A live price chart with SMA overlays and drawing tools for TLX.AU, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Biotechnology. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.